Evidence map›Paper›PMID 41098740›Full record

ArticleFrontiers in immunology2025

Mutation of conserved MHC class I cytoplasmic tyrosine affects CD8+ T cell priming, effector function, and memory response.

Yimo Sun, Yitao Tang, Priscilla Ortiz, Barbara Nassif Rausseo, Barbara Pazdrak, Lama Elzohary, Arjun Katailiha, Amjad Talukder, Cassian Yee, Richard Eric Davis and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yimo SunUT Health Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Yitao TangUT Health Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Priscilla OrtizDepartment of Melanoma Medical Oncology, The University of Texas (UT) MD Anderson Cancer Center, Houston, TX, United States.
Barbara Nassif RausseoDepartment of Melanoma Medical Oncology, The University of Texas (UT) MD Anderson Cancer Center, Houston, TX, United States.
Barbara PazdrakDepartment of Melanoma Medical Oncology, The University of Texas (UT) MD Anderson Cancer Center, Houston, TX, United States.
Lama ElzoharyDepartment of Melanoma Medical Oncology, The University of Texas (UT) MD Anderson Cancer Center, Houston, TX, United States.
Arjun KatailihaDepartment of Melanoma Medical Oncology, The University of Texas (UT) MD Anderson Cancer Center, Houston, TX, United States.
Amjad TalukderDepartment of Melanoma Medical Oncology, The University of Texas (UT) MD Anderson Cancer Center, Houston, TX, United States.
Cassian YeeDepartment of Melanoma Medical Oncology, The University of Texas (UT) MD Anderson Cancer Center, Houston, TX, United States.
Richard Eric DavisDepartment of Lymphoma-Myeloma, The University of Texas (UT) MD Anderson Cancer Center, Houston, TX, United States.
Gregory LizéeDepartment of Melanoma Medical Oncology, The University of Texas (UT) MD Anderson Cancer Center, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cytoplasmic domain of MHC class I (MHC-I) molecules contains a single, highly conserved tyrosine residue (Y320). In previous work, we found that mice expressing a Y320F-mutated form of H-2K

Indexed as

CD8-Positive T-LymphocytesHistocompatibility Antigens Class IImmunologic MemoryMutationTyrosineAnimalsAntigen PresentationDendritic CellsHLA-A2 AntigenHumansLymphocyte ActivationMiceHistocompatibility Antigens Class IHLA-A*02:01 antigenHLA-A2 AntigenTyrosinecytoplasmic tailcytotoxic T cellsdendritic cellshuman leukocyte antigen (HLA)MHC class Ityrosine phosphorylation

Identifiers

PMID41098740
PMCPMC12518231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.